文献速递性腺与生殖内分泌糖尿病

二甲双胍治疗多囊卵巢综合征孕妇:PregMet2随机双盲安慰剂对照试验

Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2019-02-18

PregMet2是在挪威、瑞典和冰岛14家医院开展的随机双盲安慰剂对照多中心试验,纳入487例18-45岁单胎PCOS孕妇,比较二甲双胍与安慰剂。妊娠期糖尿病等次要终点无显著差异。

要点

  • 事后汇总三项试验个体数据提示二甲双胍可能降低晚期流产或早产风险,需谨慎解读。

核心结论

  • 在PCOS孕妇中,自晚孕早期至分娩使用二甲双胍可能降低晚期流产和早产风险,但不能预防妊娠期糖尿病。
  • PregMet2主要分析未达统计学显著,事后合并三项试验的个体数据汇总分析才显示显著降低。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心试验,在挪威、瑞典和冰岛14家医院开展。
  • 纳入18-45岁单胎PCOS孕妇,1:1随机分配至二甲双胍组(n=244)或安慰剂组(n=243),按意向性治疗人群分析。
  • 二甲双胍用法为治疗第1周口服500 mg每日两次,第2周起增至1000 mg每日两次至分娩;研究于2012年10月19日至2017年9月1日进行。

主要发现

  • 母亲或子代严重不良事件无实质组间差异,主要研究者认为无严重不良事件与药物相关。

关键数值与推荐

  • 主要结局为晚期流产(13周至22周6天)与早产(23周至36周6天)的复合发生率。
  • 次要终点包括妊娠期糖尿病、子痫前期、妊娠期高血压及新生儿入住新生儿重症监护室的发生率。
  • 二甲双胍剂量方案:第1周500 mg每日两次,第2周起1000 mg每日两次至分娩。

临床怎么用

  • 对PCOS孕妇,二甲双胍自晚孕早期使用至分娩可能有助于降低晚期流产和早产风险,但本试验主要终点未达显著。
  • 不应期望二甲双胍预防PCOS孕妇的妊娠期糖尿病。
  • 临床决策需结合事后汇总分析的证据强度,个体化评估后与孕妇共同讨论。

局限性

  • 事后汇总分析合并了不同试验的数据,属于探索性分析,不能作为确证性证据。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an increased risk of pregnancy complications. Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group. The aim of this third randomised trial (PregMet2) was to test the hypothesis that metformin prevents late miscarriage and preterm birth in women with PCOS. METHODS: PregMet2 was a randomised, placebo-controlled, double-blind, multicentre trial done at 14 hospitals in Norway, Sweden, and Iceland. Singleton pregnant women with PCOS aged 18-45 years were eligible for inclusion. After receiving information about the study at their first antenatal visit or from the internet, women signed up individually to participate in the study. Participants were randomly assigned (1:1) to receive metformin or placebo by computer-generated random numbers. Randomisation was in blocks of ten for each country and centre; the first block had a random size between one and ten to assure masking. Participants were assigned to receive oral metformin 500 mg twice daily or placebo during the first week of treatment, which increased to 1000 mg twice daily or placebo from week 2 until delivery. Placebo tablets and metformin tablets were identical and participants and study personnel were masked to treatment allocation. The primary outcome was the composite incidence of late miscarriage (between week 13 and week 22 and 6 days) and preterm birth (between week 23 and week 36 and 6 days), analysed in the intention-to-treat population. Secondary endpoints included the incidence of gestational diabetes, preeclampsia, pregnancy-induced hypertension, and admission of the neonate to the neonatal intensive care unit. We also did a post-hoc individual participant data analysis of pregnancy outcomes, pooling data from the two previous trials with the present study. The study was registered with ClinicalTrials.gov, number NCT01587378, and EudraCT, number 2011-002203-15. FINDINGS: The study took place between Oct 19, 2012, and Sept 1, 2017. We randomly assigned 487 women to metformin (n=244) or placebo (n=243). In the intention-to-treat analysis, our composite primary outcome of late miscarriage and preterm birth occurred in 12 (5%) of 238 women in the metformin group and 23 (10%) of 240 women in the placebo group (odds ratio [OR] 0·50, 95% CI 0·22-1·08; p=0·08). We found no significant differences for our secondary endpoints, including incidence of gestational diabetes (60 [25%] of 238 women in the metformin group vs 57 [24%] of 240 women in the placebo group; OR 1·09, 95% CI 0·69-1·66; p=0·75). We noted no substantial between-group differences in serious adverse events in either mothers or offspring, and no serious adverse events were considered drug-related by principal investigators. In the post-hoc pooled analysis of individual participant data from the present trial and two previous trials, 18 (5%) of 397 women had late miscarriage or preterm delivery in the metformin group compared with 40 (10%) of 399 women in the placebo group (OR 0·43, 95% CI 0·23-0·79; p=0·004). INTERPRETATION: In pregnant women with PCOS, metformin treatment from the late first trimester until delivery might reduce the risk of late miscarriage and preterm birth, but does not prevent gestational diabetes. FUNDING: Research Council of Norway, Novo Nordisk Foundation, St Olav's University Hospital, and Norwegian University of Science and Technology.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019. PMID: 30792154. doi:10.1016/S2213-8587(19)30002-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。